FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
The Patriot Ledger4d
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
Vertex Pharmaceuticals is a biotech company based in Boston, Massachusetts. Its headquarters are in Boston's Seaport neighborhood, and it also has a research site in Cambridge's Kendall Square.
AFP5d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
BioSpace5d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq ... Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company ...
WOFL5d
FDA approves first new non-opioid pain pill in 20 years—how it works
The drug, developed by Vertex Pharmaceuticals ... A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. ( ...
pharmaphorum3d
AI helping us make smarter, faster decisions, says Novartis R&D chief
ophthalmology pharmaceuticals, oncology and biosimilars units. Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel ...
pharmaphorum4d
A history of Bayer
Leverkusen also became the headquarters for the I.G.'s pharmaceutical sales association ... cheaper versions of its cancer drug, Nexavar. Vertex's gene-editing therapy for sickle cell disease ...
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...